Ventas

VTR · NYSE

$86.49+$1.98 (+2.34%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $84.51

VTR analyst rating

BuyConsensus of 16 analysts over the last 12 months. 81% rate it a buy.

Strong buy0
Buy13
Hold3
Underperform0
Sell0

12-month price target · 23 analysts

Average $104.14 (+20.4% upside)

Low: $90.90
Now: $86.49
High: $118.65

Upgrades and downgrades

The latest rating actions, newest first

VTR analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Wells Fargo	Oct 19, 2026	Maintains	Overweight	$104.00 → $96.00	48%
Barclays	Oct 13, 2026	Maintains	Equal-Weight	$102.00 → $91.00	38%
Evercore ISI Group	Sep 21, 2026	Maintains	Outperform	$101.00 → $100.00	45%
Jefferies	Sep 15, 2026	Initiates	Buy	$102.00	33%
Scotiabank	Sep 2, 2026	Maintains	Sector Perform	$93.00 → $95.00	47%
Wells Fargo	Sep 1, 2026	Maintains	Overweight	$96.00 → $104.00	51%
Barclays	Aug 31, 2026	Maintains	Equal-Weight	$99.00 → $102.00	38%
RBC Capital	Aug 14, 2026	Maintains	Outperform	$98.00 → $99.00	58%
BMO Capital	Aug 11, 2026	Maintains	Outperform	$105.00 → $107.00	47%
Citigroup	Aug 4, 2026	Maintains	Buy	$100.00 → $110.00	44%

The case for and against

Updated Oct 18, 2026

Bull case

Ventas is attractive because its nearly 1,400-property healthcare portfolio is diversified across senior housing, medical office, hospitals, life science, and skilled nursing, with about 100 properties in Canada and the United Kingdom and mortgage and loan assets adding another layer of income. Strong SHOP operating momentum is the clearest fundamental driver, with same-store NOI growth of 15.4% in 1Q26 and 15.9% YTD, while occupancy gains and a 97% occupancy level in the LGM portfolio support durable cash flow expansion. The outlook is further reinforced by a healthier balance sheet, with net debt to EBITDA down to 5.0x in 1Q26, and by an active investment pipeline that could support roughly $3.0 billion to $4.5 billion of annual acquisitions and continued AFFO growth.

Bear case

Ventas is facing a less attractive risk-reward profile because its growth is increasingly reliant on continued capital deployment into a more competitive acquisition market, even as management raised 2026 investment guidance to $4.5 billion after completing $3.2 billion YTD. The outlook is further pressured by declining cap rates, which management still finds in the mid-6.0% range but are expected to drift to 6.25% in 2027 and 6.00% in 2028, potentially squeezing future accretion. In addition, the stock remains exposed to regulatory and funding uncertainty, including potential cuts to government-funded programs and NIH budget reductions that could affect its 8% R&I/Wexford exposure.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.